Perspectives on salvage therapy for non-small-cell lung cancer

Federico Cappuzzo, Giovanna Finocchiaro, Rocco Trisolini, Luca Toschi, Stefania Bartolini, Giulio Metro, Lucio Crinò

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Platinum-based chemotherapy offers a modest survival advantage over best supportive care in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Despite the survival benefit associated with first-line chemotherapy, the majority of patients will experience relapse or disease progression. In clinical practice, an increasing number of patients maintain a good performance status after first-line treatment and are eligible for further treatments. Docetaxel (Taxotere) at 75 mg/m 2 given once every 3 weeks has been the standard of care for second-line chemotherapy since the year 2000. Pemetrexed (Alimta) is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A large phase III study comparing docetaxel to pemetrexed in second-line therapy demonstrated that pemetrexed is equally active and less toxic than docetaxel. Based on these results, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC. Progress made in the field of molecular biology has led to the identification of drugs active against specific cellular targets. Gefitinib (Iressa) and erlotinib (Tarceva) are both orally active tyrosine kinase inhibitors of the epidermal growth factor receptor. Phase II and III trials have demonstrated that these agents are active particularly in a subgroup of patients with specific biologic characteristics. Both drugs have been approved for the treatment of pretreated NSCLC. Other drugs, such as cetuximab (Erbitux) and bevacizumab (Avastin) have shown promising activity in NSCLC and are currently being tested in clinical trials.

Original languageEnglish
Pages (from-to)989-995
Number of pages7
JournalOncology
Volume19
Issue number8
Publication statusPublished - 2005

Fingerprint

Pemetrexed
docetaxel
Salvage Therapy
Non-Small Cell Lung Carcinoma
Drug Therapy
Pharmaceutical Preparations
Folic Acid Antagonists
Therapeutics
Survival
Poisons
Standard of Care
Platinum
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Disease Progression
Molecular Biology
Clinical Trials
Recurrence

ASJC Scopus subject areas

  • Oncology

Cite this

Cappuzzo, F., Finocchiaro, G., Trisolini, R., Toschi, L., Bartolini, S., Metro, G., & Crinò, L. (2005). Perspectives on salvage therapy for non-small-cell lung cancer. Oncology, 19(8), 989-995.

Perspectives on salvage therapy for non-small-cell lung cancer. / Cappuzzo, Federico; Finocchiaro, Giovanna; Trisolini, Rocco; Toschi, Luca; Bartolini, Stefania; Metro, Giulio; Crinò, Lucio.

In: Oncology, Vol. 19, No. 8, 2005, p. 989-995.

Research output: Contribution to journalArticle

Cappuzzo, F, Finocchiaro, G, Trisolini, R, Toschi, L, Bartolini, S, Metro, G & Crinò, L 2005, 'Perspectives on salvage therapy for non-small-cell lung cancer', Oncology, vol. 19, no. 8, pp. 989-995.
Cappuzzo F, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G et al. Perspectives on salvage therapy for non-small-cell lung cancer. Oncology. 2005;19(8):989-995.
Cappuzzo, Federico ; Finocchiaro, Giovanna ; Trisolini, Rocco ; Toschi, Luca ; Bartolini, Stefania ; Metro, Giulio ; Crinò, Lucio. / Perspectives on salvage therapy for non-small-cell lung cancer. In: Oncology. 2005 ; Vol. 19, No. 8. pp. 989-995.
@article{040650056d514c91bc725bd2c7681318,
title = "Perspectives on salvage therapy for non-small-cell lung cancer",
abstract = "Platinum-based chemotherapy offers a modest survival advantage over best supportive care in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Despite the survival benefit associated with first-line chemotherapy, the majority of patients will experience relapse or disease progression. In clinical practice, an increasing number of patients maintain a good performance status after first-line treatment and are eligible for further treatments. Docetaxel (Taxotere) at 75 mg/m 2 given once every 3 weeks has been the standard of care for second-line chemotherapy since the year 2000. Pemetrexed (Alimta) is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A large phase III study comparing docetaxel to pemetrexed in second-line therapy demonstrated that pemetrexed is equally active and less toxic than docetaxel. Based on these results, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC. Progress made in the field of molecular biology has led to the identification of drugs active against specific cellular targets. Gefitinib (Iressa) and erlotinib (Tarceva) are both orally active tyrosine kinase inhibitors of the epidermal growth factor receptor. Phase II and III trials have demonstrated that these agents are active particularly in a subgroup of patients with specific biologic characteristics. Both drugs have been approved for the treatment of pretreated NSCLC. Other drugs, such as cetuximab (Erbitux) and bevacizumab (Avastin) have shown promising activity in NSCLC and are currently being tested in clinical trials.",
author = "Federico Cappuzzo and Giovanna Finocchiaro and Rocco Trisolini and Luca Toschi and Stefania Bartolini and Giulio Metro and Lucio Crin{\`o}",
year = "2005",
language = "English",
volume = "19",
pages = "989--995",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - Perspectives on salvage therapy for non-small-cell lung cancer

AU - Cappuzzo, Federico

AU - Finocchiaro, Giovanna

AU - Trisolini, Rocco

AU - Toschi, Luca

AU - Bartolini, Stefania

AU - Metro, Giulio

AU - Crinò, Lucio

PY - 2005

Y1 - 2005

N2 - Platinum-based chemotherapy offers a modest survival advantage over best supportive care in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Despite the survival benefit associated with first-line chemotherapy, the majority of patients will experience relapse or disease progression. In clinical practice, an increasing number of patients maintain a good performance status after first-line treatment and are eligible for further treatments. Docetaxel (Taxotere) at 75 mg/m 2 given once every 3 weeks has been the standard of care for second-line chemotherapy since the year 2000. Pemetrexed (Alimta) is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A large phase III study comparing docetaxel to pemetrexed in second-line therapy demonstrated that pemetrexed is equally active and less toxic than docetaxel. Based on these results, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC. Progress made in the field of molecular biology has led to the identification of drugs active against specific cellular targets. Gefitinib (Iressa) and erlotinib (Tarceva) are both orally active tyrosine kinase inhibitors of the epidermal growth factor receptor. Phase II and III trials have demonstrated that these agents are active particularly in a subgroup of patients with specific biologic characteristics. Both drugs have been approved for the treatment of pretreated NSCLC. Other drugs, such as cetuximab (Erbitux) and bevacizumab (Avastin) have shown promising activity in NSCLC and are currently being tested in clinical trials.

AB - Platinum-based chemotherapy offers a modest survival advantage over best supportive care in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Despite the survival benefit associated with first-line chemotherapy, the majority of patients will experience relapse or disease progression. In clinical practice, an increasing number of patients maintain a good performance status after first-line treatment and are eligible for further treatments. Docetaxel (Taxotere) at 75 mg/m 2 given once every 3 weeks has been the standard of care for second-line chemotherapy since the year 2000. Pemetrexed (Alimta) is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A large phase III study comparing docetaxel to pemetrexed in second-line therapy demonstrated that pemetrexed is equally active and less toxic than docetaxel. Based on these results, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC. Progress made in the field of molecular biology has led to the identification of drugs active against specific cellular targets. Gefitinib (Iressa) and erlotinib (Tarceva) are both orally active tyrosine kinase inhibitors of the epidermal growth factor receptor. Phase II and III trials have demonstrated that these agents are active particularly in a subgroup of patients with specific biologic characteristics. Both drugs have been approved for the treatment of pretreated NSCLC. Other drugs, such as cetuximab (Erbitux) and bevacizumab (Avastin) have shown promising activity in NSCLC and are currently being tested in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=28444482719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444482719&partnerID=8YFLogxK

M3 - Article

C2 - 16131043

AN - SCOPUS:28444482719

VL - 19

SP - 989

EP - 995

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 8

ER -